<DOC>
	<DOCNO>NCT00733720</DOCNO>
	<brief_summary>The purpose study determine opioid agonist effect dose 4/1 mg , 8/2 mg , 16/4 mg buprenorphine/naloxone completely block 50 mg oral naltrexone . This study provide data support design similar study depot formulation naltrexone ultimately study combination treatment cocaine dependence .</brief_summary>
	<brief_title>Buprenorphine Naltrexone-P1 A-Cocaine</brief_title>
	<detailed_description />
	<mesh_term>Cocaine-Related Disorders</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Buprenorphine , Naloxone Drug Combination</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Provide write informed consent Be male/female age 1855 Be good physical mental health determine interview physical exam Have body mass index 18 30 , inclusive Have oral cavity pathology would interfere sublingual absorption buprenorphine/naloxone placebo Have negative qualitative urine toxicology screen opioids , cocaine , benzodiazepine , barbiturates prior administration first dose naltrexone Be able comply protocol requirement If female , negative pregnancy test agree use acceptable method birth control date consent two week last administration study drug placebo please contact site information</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>